-

Telesair’s Bonhawa High Flow Oxygen Receives Approval from Thai FDA

Unique High Flow Oxygen Technology Now Available for Use in Thailand

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., an innovator of next-generation respiratory care, and JPP Care, a leading Thai distributor of respiratory devices, jointly announced today that Telesair’s Bonhawa High Flow Oxygen Therapy (HFOT) system has been approved by Thailand’s Food and Drug Administration (Thai FDA) for use in the treatment of patients with respiratory insufficiency.

The light and compact Bonhawa HFOT device features an extended flow range up to 80 L/pm, a simple disinfection process and an easy-to-use touchscreen, allowing greater therapeutic range, efficient disinfection and the ability to visualize patient settings and data from outside the room.

“Thailand is an important market for us,” said Bryan Liu, CEO of Telesair. “High flow oxygen therapy has become widely accepted at Thai medical centers of excellence and there are many clinicians there that we are eager to work with. Partnering with JPP and its team of knowledgeable specialists also means we will be able to help reach the maximum number of patients while learning about the potential impact of our extended flow range to 80 L/pm.”

“We are excited to represent Telesair’s Bonhawa device here in Thailand because of its enhanced clinical range and the significant potential to innovatively improve the efficiency of patient care and device cleaning,” said Piangpim (Joy) Kirativej, Founder and CEO of JPP Care.

“This latest success was truly a team effort and with our Bonhawa HFOT system now available in Thailand, we’re just getting started,” added Liu. “We’re working toward similar approvals in several other countries, establishing partnerships and studies with multiple institutions, and moving forward with the development of our second-generation home oxygen therapy device. The future for Telesair is very bright!”

Telesair, Inc. is a Southern California-based, high-growth company that is developing breakthrough solutions to help move patients from hospital to home sooner by providing compact, mobile respiratory care solutions to hospitals, long-term care and skilled nursing facilities, rural health providers, and in the homecare setting. Led by respiratory veterans in both R&D and commercialization, the company has developed a next-gen, advanced respiratory treatment system platform based on state-of-the-art sensor fusion technologies and innovative pneumatics. Telesair’s solutions are designed to elevate the existing standard of care by improving outcomes for patients and the health system. Learn more at Telesair.com.

Contacts

Media Contact: Paul Williams, MediaLine Communications
paul@medialinecommunications.com, 310/569-0023

Telesair, Inc.


Release Versions

Contacts

Media Contact: Paul Williams, MediaLine Communications
paul@medialinecommunications.com, 310/569-0023

Social Media Profiles
More News From Telesair, Inc.

Telesair Receives FDA Clearance for Bonhawa High Flow Oxygen Therapy System

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., a technology leader in the respiratory industry, announced today that it has received FDA clearance to market its Bonhawa High Flow Oxygen Therapy (HFOT) system, designed to enhance the treatment of patients with respiratory insufficiency. Bonhawa is now the only purpose-built high flow system to receive both the CE Mark/European Medical Device Regulation and FDA 510(k) clearance. Bonhawa gives healthcare providers and their patients in the US an...

Telesair Receives CE Mark for Bonhawa High Flow Oxygen Therapy System

IRVINE, Calif.--(BUSINESS WIRE)--Telesair, Inc., an innovator of next generation respiratory technology, announced today that it has received CE (Conformité Européenne) Marking under the European Medical Device Regulation for its Bonhawa High Flow Oxygen Therapy (HFOT) system for use in the treatment of patients with respiratory insufficiency. The Bonhawa HFOT is one of the first respiratory therapeutic devices from a US based company to receive CE Mark under the new European Medical Device Reg...

Pasaca Capital and Honeywell Back Telesair with $22M Series A Round

IRVINE, Calif.--(BUSINESS WIRE)--Honeywell and Telesair, Inc., an innovator of next generation respiratory care, jointly announced today that Telesair, Inc. has closed a total of $22 million Series A round financing led by Pasaca Capital with participation from existing and new investors such as ZhenCheng Capital, Shangbay Capital, Device of Tomorrow Capital, Berkeley Catalyst Fund and Ultrastar Ventures LLC. The round of funding will support the commercialization of Telesair’s Bonhawa Respirat...
Back to Newsroom